Michael Loberg
Keine laufenden Positionen mehr
Vermögen: 634 399 $ am 30.04.2024
Karriereverlauf von Michael Loberg
Ehemalige bekannte Positionen von Michael Loberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IGM BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 01.09.2015 | 01.08.2018 |
Vorsitzender | 01.08.2018 | 03.10.2023 | |
Independent Dir/Board Member | - | 03.10.2023 | |
ARQULE, INC. | Direktor/Vorstandsmitglied | 01.01.2007 | 01.01.2020 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Direktor/Vorstandsmitglied | 03.06.2011 | 01.07.2014 |
Vorsitzender | 31.05.2010 | 03.06.2011 | |
Independent Dir/Board Member | 01.03.2006 | 01.07.2014 | |
Präsident | 01.03.2006 | 31.05.2010 | |
AMAG PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 15.05.2009 | 15.05.2009 |
NETMED, INC. | Präsident | 01.01.1997 | 01.03.2006 |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Direktor/Vorstandsmitglied | 01.09.1997 | 01.03.2006 |
Vorstandsvorsitzender | 01.09.1997 | 01.03.2006 | |
Präsident | 01.09.2003 | 01.03.2006 | |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.1997 | 01.01.1997 |
E.R. Squibb & Sons Research & Development | Direktor/Vorstandsmitglied | 01.01.1997 | 01.01.1997 |
Corporate Officer/Principal | 01.01.1997 | 01.01.1997 | |
University of Maryland | Corporate Officer/Principal | 01.01.1973 | 01.01.1979 |
░░ ░░ ░░░░░░ ░ ░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - | |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Michael Loberg
Washington University in St. Louis | Doctorate Degree |
Trinity College (Connecticut) | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 14 |
Operativ
Director/Board Member | 8 |
President | 3 |
Corporate Officer/Principal | 3 |
Sektoral
Health Technology | 9 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
NETMED, INC. | Health Technology |
IGM BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
ArQule, Inc.
ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
Kereos, Inc.
Kereos, Inc. Pharmaceuticals: MajorHealth Technology Kereos, Inc. develops and manufactures biotechnology products. The firm focuses on nanodroplet technology that allows delivery of a range of drug compounds to a target in the body for the treatment of diseases. The company was founded by Samuel A. Wickline and Gregory M. Lanza in 1999 and is headquartered in St. Louis, MO. | Health Technology |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
E. R. Squibb & Sons LLC | |
E.R. Squibb & Sons Research & Development |
- Börse
- Insiders
- Michael Loberg
- Erfahrung